Replies to post #215198 on Biotech Values

[DewDiligence]

MRTX -8% despite inking Sitravatinib deal with BGNE for Asia/Pacific:

https://globenewswire.com/news-release/2018/01/08/1284828/0/en/BeiGene-and-Mirati-Therapeutics-Announce-Exclusive-License-Agreement-for-Sitravatinib-in-the-Asia-Pacific-Region.html

The up-front cash is only $10M, which could be the impetus for the sell-off.